Himalayas-1: Rinzimetostat, an Allosteric PRC2 Inhibitor, + Daro: 🌎 Ph 3 RC in mCRPC Previously Treated with Abiraterone @urotoday #ESMO26 @quimmateo

Zach Klaassen· @zklaassen_md · X·2026-10-23 20:21· 2 days agoScore70

Body · original

📌n=600
📌1:1 to rinzimetostat + Daro vs physician’s choice of ARPI or docetaxel
📌Prim EP: rPFS
📌Sec EP: OS

309 views · 4 likes · 5 reposts · 0 replies

Conference abstracts

2300TIPNCT07365995 NCT07365995 NCT07365995matched by Metastatic prostate cancer

BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer

https://esmocongress.esmo.org

LBA15matched by Proffered paper 2: Breast cancer, early and advanced stage

Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

https://esmocongress.esmo.org

NCT04884282NCT04884282matched by - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

Source: Zach Klaassen · x.com